COLL Collegium Pharma: Net earnings per share for the last 12 months

Collegium Pharmaceutical Inc (COLL) - corporate logo

Management stability at Collegium Pharmaceutical (COLL) serves as a growth catalyst, as evidenced by the YoY EPS volatility over the last 12 months with the metric standing at -33.60. The business relies on the acquisition of painkiller brands and partnerships with clinics. However, a strictly regulated government market and the expansion of generics create serious challenges, requiring the company to constantly adapt its development strategy.

Collegium Pharmaceutical Inc (COLL) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/16/2026

COLL (Collegium Pharmaceutical): analytical breakdowns and indicator data

Fundamental company valuation:COLL, Collegium Pharmaceutical, Inc.
Flagship merchandise of Collegium Corp

This indicator tracks the dynamics of the rolling twelve-month net earnings per share, allowing for the identification of market imbalances and the avoidance of purchasing an asset at its peak overheating. By analyzing the rolling year-over-year EPS chart, an investor can assess the resilience of Collegium Pharmaceutical (COLL) to geopolitical disruptions in raw material supplies, which determines the company's actual fundamental reliability.